BRPI0915667A2 - ligante, fragmentos scfv e fab, anticorpo, composição farmacêutica, ácido nucleico, molécula de ácido nucleico, vetor, célula hospedeira, método para produção do ligante, método de tratamento, antiligante, método de detecção do antiligante em uma amostra biológica, kit de imunoesaio para detecção do antiligante, uso do kit de imunoensaio - Google Patents

ligante, fragmentos scfv e fab, anticorpo, composição farmacêutica, ácido nucleico, molécula de ácido nucleico, vetor, célula hospedeira, método para produção do ligante, método de tratamento, antiligante, método de detecção do antiligante em uma amostra biológica, kit de imunoesaio para detecção do antiligante, uso do kit de imunoensaio

Info

Publication number
BRPI0915667A2
BRPI0915667A2 BRPI0915667A BRPI0915667A BRPI0915667A2 BR PI0915667 A2 BRPI0915667 A2 BR PI0915667A2 BR PI0915667 A BRPI0915667 A BR PI0915667A BR PI0915667 A BRPI0915667 A BR PI0915667A BR PI0915667 A2 BRPI0915667 A2 BR PI0915667A2
Authority
BR
Brazil
Prior art keywords
antiligant
binder
nucleic acid
immunoassay kit
detection
Prior art date
Application number
BRPI0915667A
Other languages
English (en)
Inventor
Bernhardt Alois Lang
Corinne Bernard
Hervé Perron
Jean-Baptiste Bertrand
Original Assignee
Geneuro Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneuro Sa filed Critical Geneuro Sa
Publication of BRPI0915667A2 publication Critical patent/BRPI0915667A2/pt
Publication of BRPI0915667B1 publication Critical patent/BRPI0915667B1/pt
Publication of BRPI0915667B8 publication Critical patent/BRPI0915667B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

abstract not avaible
BRPI0915667A 2008-07-08 2009-07-08 ligante, fragmentos scfv e fab, anticorpo, composição farmacêutica, ácido nucleico, molécula de ácido nucleico, vetor, célula hospedeira, método para produção do ligante, ligante, composição farmacêutica, método de detecção do antiligante em uma amostra biológica e kit de imunoensaio para detecção do antiligante em uma amostra biológica BRPI0915667B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12961308P 2008-07-08 2008-07-08
US61/129613 2008-07-08
US20258109P 2009-03-13 2009-03-13
US61/202581 2009-03-13
US21318909P 2009-05-15 2009-05-15
US61/213189 2009-05-15
PCT/EP2009/058663 WO2010003977A1 (en) 2008-07-08 2009-07-08 Therapeutic use of specific ligand in msrv associated diseases

Publications (3)

Publication Number Publication Date
BRPI0915667A2 true BRPI0915667A2 (pt) 2017-01-17
BRPI0915667B1 BRPI0915667B1 (pt) 2020-10-13
BRPI0915667B8 BRPI0915667B8 (pt) 2021-05-25

Family

ID=41165692

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915667A BRPI0915667B8 (pt) 2008-07-08 2009-07-08 ligante, fragmentos scfv e fab, anticorpo, composição farmacêutica, ácido nucleico, molécula de ácido nucleico, vetor, célula hospedeira, método para produção do ligante, ligante, composição farmacêutica, método de detecção do antiligante em uma amostra biológica e kit de imunoensaio para detecção do antiligante em uma amostra biológica

Country Status (24)

Country Link
US (4) US8715656B2 (pt)
EP (2) EP3211005B1 (pt)
JP (3) JP6058264B2 (pt)
KR (1) KR101682040B1 (pt)
CN (1) CN102143975B (pt)
AU (1) AU2009268025B2 (pt)
BR (1) BRPI0915667B8 (pt)
CA (1) CA2729869C (pt)
CY (2) CY1119185T1 (pt)
DK (1) DK3211005T3 (pt)
EA (1) EA024655B1 (pt)
ES (2) ES2633965T3 (pt)
HR (2) HRP20171067T1 (pt)
HU (2) HUE033803T2 (pt)
IL (1) IL210204A (pt)
LT (2) LT3211005T (pt)
MX (1) MX2010014319A (pt)
NZ (1) NZ590515A (pt)
PL (2) PL3211005T3 (pt)
PT (2) PT2315777T (pt)
SI (2) SI2315777T1 (pt)
SM (1) SMT201700366T1 (pt)
WO (1) WO2010003977A1 (pt)
ZA (1) ZA201100446B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378407T3 (es) 2006-09-01 2012-04-12 Therapeutic Human Polyclonals, Inc. Aumento de la expresión de inmunoglobulina humana o humanizada en animales transgénicos no humanos
DK3211005T3 (da) * 2008-07-08 2021-06-07 Geneuro Sa Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
UA119032C2 (uk) * 2012-10-02 2019-04-25 Женеро Са Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w
EP2949342A1 (en) * 2014-05-28 2015-12-02 Geneuro SA Antiretroviral drug targeting human endogenous retrovirus
CN113862300A (zh) * 2015-10-29 2021-12-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
JP2018028538A (ja) * 2016-08-12 2018-02-22 公立大学法人名古屋市立大学 統合失調症とその関連疾患の診断用マーカー及びその使用
WO2019201908A1 (en) 2018-04-17 2019-10-24 Geneuro Sa Method for the detection of the soluble hydrophilic oligomeric form of herv-w envelope protein
EP3916015A1 (en) * 2020-05-28 2021-12-01 Geneuro SA Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases
CN113940993B (zh) * 2021-12-20 2022-02-22 深圳万可森生物科技有限公司 一种鲈鱼弹状病毒g2-2m亚单位疫苗及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
HU218465B (hu) 1989-08-09 2000-09-28 Dekalb Genetics Corporation Eljárások és kompozíciók stabilan transzformált, termő egyszikű növények és sejtjeik előállítására
US7473423B2 (en) * 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2734842B1 (fr) 1995-06-02 1998-02-27 Rhone Poulenc Agrochimie Sequence adn d'un gene de l'hydroxy-phenyl pyruvate dioxygenase et obtention de plantes contenant un gene de l'hydroxy-phenyl pyruvate dioxygenase, tolerantes a certains herbicides
FR2736926B1 (fr) 1995-07-19 1997-08-22 Rhone Poulenc Agrochimie 5-enol pyruvylshikimate-3-phosphate synthase mutee, gene codant pour cette proteine et plantes transformees contenant ce gene
JP2003512844A (ja) * 1999-10-28 2003-04-08 ユニヴェルシテ・ドゥ・ジュネーブ 多発性硬化症関連スーパー抗原
EP1629013B1 (en) * 2003-05-31 2018-01-24 Amgen Research (Munich) GmbH Pharmaceutical composition comprising a bispecific antibody specific for epcam
FR2865403B1 (fr) * 2004-01-23 2009-06-12 Biomerieux Sa Composition pour le traitement d'une pathologie associee a la msrv/herv-w
CA2544692C (en) 2004-07-09 2014-04-01 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
US7579187B2 (en) 2004-09-06 2009-08-25 Kyoma Hakko Kirin Co., Ltd. Anti-A33 antibody
JPWO2006067847A1 (ja) * 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
WO2006138627A2 (en) 2005-06-16 2006-12-28 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
EP1921137A4 (en) 2005-06-21 2011-01-26 Med & Biological Lab Co Ltd ANTIBODIES WITH INHIBITOR EFFECT ON THE FORMATION OF AMYLOID FIBRILLES
FR2912314B1 (fr) * 2007-02-09 2012-08-03 Geneuro Sa Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.
DK3211005T3 (da) * 2008-07-08 2021-06-07 Geneuro Sa Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme

Also Published As

Publication number Publication date
PL2315777T3 (pl) 2017-10-31
WO2010003977A1 (en) 2010-01-14
US20180057569A1 (en) 2018-03-01
PT2315777T (pt) 2017-07-25
JP2011527887A (ja) 2011-11-10
DK3211005T3 (da) 2021-06-07
EA024655B1 (ru) 2016-10-31
ES2633965T3 (es) 2017-09-26
SI2315777T1 (sl) 2017-09-29
JP6495361B2 (ja) 2019-04-03
HRP20171067T1 (hr) 2017-10-06
BRPI0915667B8 (pt) 2021-05-25
US9815888B2 (en) 2017-11-14
KR20110031969A (ko) 2011-03-29
AU2009268025B2 (en) 2014-07-31
IL210204A0 (en) 2011-03-31
BRPI0915667B1 (pt) 2020-10-13
ZA201100446B (en) 2012-01-25
PT3211005T (pt) 2021-06-15
US8715656B2 (en) 2014-05-06
AU2009268025A1 (en) 2010-01-14
HUE033803T2 (en) 2018-01-29
NZ590515A (en) 2013-01-25
EP3211005B1 (en) 2021-03-17
JP6058264B2 (ja) 2017-01-11
LT3211005T (lt) 2021-08-25
HRP20210892T1 (hr) 2021-11-26
CY1124281T1 (el) 2022-07-22
KR101682040B1 (ko) 2016-12-02
US20170107274A1 (en) 2017-04-20
US20140220026A1 (en) 2014-08-07
JP2017158550A (ja) 2017-09-14
JP6109869B2 (ja) 2017-04-05
EA201100160A1 (ru) 2011-08-30
HK1158232A1 (en) 2012-07-13
EP2315777B1 (en) 2017-04-26
EP2315777A1 (en) 2011-05-04
US9550824B2 (en) 2017-01-24
EP3211005A1 (en) 2017-08-30
CA2729869A1 (en) 2010-01-14
CY1119185T1 (el) 2018-02-14
CN102143975A (zh) 2011-08-03
IL210204A (en) 2015-03-31
JP2015157812A (ja) 2015-09-03
HUE054712T2 (hu) 2021-09-28
US10059758B2 (en) 2018-08-28
HK1243436A1 (en) 2018-07-13
US20110243962A1 (en) 2011-10-06
ES2875762T3 (es) 2021-11-11
LT2315777T (lt) 2017-10-25
MX2010014319A (es) 2011-05-19
CN102143975B (zh) 2014-12-31
CA2729869C (en) 2018-02-13
SMT201700366T1 (it) 2017-09-07
PL3211005T3 (pl) 2021-11-29
SI3211005T1 (sl) 2021-06-30

Similar Documents

Publication Publication Date Title
BR112015014833B8 (pt) Anticorpo isolado ou fragmento de ligação, ácido nucleico, método in vitro, kit e composição de anticorpo
BRPI0922106A2 (pt) anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
BRPI0919377A2 (pt) anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
BRPI0905761A2 (pt) Anticorpo humanizado ou fragmento de ligação ao mesmo, ácido nucléico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou o fragmento de ligação ao mesmo, composição, método para tratar uma doença ou distúrbio mediado por vwf em um indivíduo, uso de um anticorpo humanizado ou fragmento de ligação do mesmo, método para administração do anticorpo humanizado ou fragmento de ligação do mesmo, artigo de fabricação e kit
BRPI0819211A2 (pt) Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo
BRPI0816094A2 (pt) Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
CL2011002003A1 (es) Anticuerpo humanizado o fragmentos de este, que se unen al receptor del factor de crecimiento epidérmico (egfr) en una expresión aberrante o al egfr truncado ?2-7; célula huésped; composición farmacéutica que lo comprende; y su uso para tratar tratar cáncer.
CL2008002444A1 (es) Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
BRPI0916964A2 (pt) polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
CL2014001293A1 (es) Anticuerpo monocional o fragmento enlazante a antigeno del mismo, especifico para proteinas de citomegalovirus humano (hcmv); molecula de acido nucleico que lo codifica; celula huesped; metodo de produccion; composicion que lo comprende; y su uso para el tratamiento de infeccion por hcmv (div sol 84-2011)
CL2013001403A1 (es) Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
BR112015014751A2 (pt) anticorpos anti-tau humanos
MY167795A (en) Tdp-43 specefic binding molecules
BR112013004579A2 (pt) proteína de ligação à mmp9, ácido nucleico, vetor, célula, composição farmacêutica e seu uso bem como método de detecção da expressão mmp9
BRPI0906903B8 (pt) anticorpo monoclonal e método de detecção da expressão de cd70
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
BR112012031071A2 (pt) 8-proteínas de ligação à il-1
EP2275443A4 (en) ANTIGEN BINDING MOLECULE THAT IS ABLE TO REPEAT TWO OR MORE BONDING ANTIGENMOLEKÜLE
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
CL2013002888A1 (es) Anticuerpo que se une peptido antigenico que se obtiene a partir de una proteina tau; composicion farmaceutica que comprende; uso para tratar trastorno o enfermedad neurodegenerativa;kit de ensayo, linea celular (div 2457-2011).
CL2011002228A1 (es) Aparato para el analisis integrado de acidos nucleicos en tiempo real, y metodo de detecicion de dichas moleculas.
BR112012012911A2 (pt) métodos para triar uma molécula capaz de ligação a cd4, para produzir uma composição terapêutica, para triar um anticorpo ou fragmento de anticorpo, in vitro para a ativação de células t regulatórias cd4+cd25+, para tratar um indivíduo, e para triar a presença de células regulatórias t cd4+cd25+ em uma amostra, composição terapêutica, anticorpo ou fragmento de anticorpo, peptídeo isolado, mimótopo de um peptídeo isolado, ácido nucleico, vetor, célula hospedeira ou hibridoma, usos de um anticorpo ou fragmento de anticorpo, do peptídeo isolado e de uma célula t regulatória cd4+cd25+, célula t regulatória cd4+cd25+, e, kit.
NO20082524L (no) Biologisk materiale og anvendelse av samme
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF